Navigation Links
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
Date:9/22/2009

THOUSAND OAKS, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC. These results were presented at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 14LBA).

The addition of Vectibix to FOLFIRI significantly improved median PFS (co-primary endpoint) by two months (5.9 versus 3.9 months for patients treated with FOLFIRI alone, hazard ratio 0.73, p=0.004) in patients with KRAS wild-type mCRC. Although numerically greater (14.5 months versus 12.5 months; hazard ratio 0.85), the improvement in median overall survival (co-primary endpoint) in the Vectibix arm did not achieve statistical significance (p=0.115) in the same patient population.

Further, the addition of Vectibix to FOLFIRI resulted in greater than a three-fold improvement (35 percent versus 10 percent) in response rate in the KRAS wild-type patient population as measured by a blinded central review.

"This study showed that Vectibix can be safely administered in combination with FOLFIRI chemotherapy. Vectibix delayed disease progression by more than half compared to FOLFIRI alone in patients with previously treated KRAS wild-type colorectal cancer," said Marc Peeters, M.D., Ph.D., coordinator of Digestive Oncology Unit, University Hospital Ghent and the study's principal investigator. "Further, the response rate seen in this trial is among the highest ever re
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
2. Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
3. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
4. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
5. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
6. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
7. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
8. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... The Indiana Medical Device Manufacturers Council and the Indiana ... Forum to state legislators. The new policy forum was ... Indianapolis and featured two panel ... and State Sen. Brandt Hershman . Legislators also ... & Development Center, which is under construction on its ...
(Date:8/31/2015)... PHOENIX , Aug. 31, 2015  DICOM ... announced today that it was recognized as a ... Radiology software.  The awards are sponsored ... and related professionals in the medical imaging industry.  ... for radiology professionals to acknowledge the contributions of ...
(Date:8/31/2015)... , Aug. 31, 2015 Pepperl+Fuchs, ... has acquired MACTek Corporation, a leading provider of ... Pepperl+Fuchs, strategy to further extend its integrated solutions ... market.    "We are pleased to ... existing portfolio," said Jim Bolin , Pepperl+Fuchs, ...
Breaking Medicine Technology:Indiana Lt. Gov. Sue Ellspermann and State Sen. Brandt Hershman Kick Off New Life Sciences Policy Series 2Indiana Lt. Gov. Sue Ellspermann and State Sen. Brandt Hershman Kick Off New Life Sciences Policy Series 3DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2
... with HALO device leads to 100% patient response ... ... Calif., May 20 BARRX Medical, Inc., a global,technology leader in ... which report a 100% eradication,rate for early esophageal cancer and pre-cancerous ...
... Technologies,Inc. (Amex: PTN ) announced today that ... study of PL-3994, a novel, long-acting natriuretic peptide,receptor ... The study is placebo-controlled and double-blinded, and will ... many as 35 subjects will be,included, with six ...
Cached Medicine Technology:Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination 2Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination 3Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994 2Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994 3
(Date:8/31/2015)... ... September 01, 2015 , ... AthleticTraining.com, provider of CEUs for ... of new premium on-demand video Evidence Based Practice courses that ... 2014 must complete 50 CEUs before December 31, 2015, which must include at ...
(Date:8/31/2015)... ... September 01, 2015 , ... The PT Outcomes Registry ... relevant measures for physical therapy patients. The Registry is being developed by the American ... stated "We are happy to be selected to contribute FOTO Outcomes measures as one ...
(Date:8/31/2015)... NJ (PRWEB) , ... September 01, 2015 , ... ... spine to eliminate chronic back pain – once required a long, arduous recovery. ... shorter hospital stay, less pain, less blood loss and minimal muscle damage. These ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... released their latest predictive use case focused on helping hospital perform under the ... this program, hospital payments are adjusted based on performance across four domains related ...
(Date:8/31/2015)... ... August 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly announces ... and Influence by Modern Luxury’s The Atlantan Magazine. , This award for ... Kathy King. Her idea and vision to bring to Atlanta a true luxury ...
Breaking Medicine News(10 mins):Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3
... WASHINGTON, July 8 As part of a clean-energy transformation, ... of its $1.4 billion in funds from the American Recovery ... energy conservation. , , "These investments help spur ... environmental footprint," Secretary of Veterans Affairs Eric K. Shinseki said. ...
... 2009 - The International Diabetes Federation (IDF), the International ... (WHF) called today on the UN,s Economic and Social ... fastest growing threat by non-communicable diseases (NCDs) to global ... cancer and chronic respiratory disease, cause 60% of all ...
... The results of a study published in the current ... the findings of a white paper released last month by ... potentially lifesaving qualities of cholesterol lowering drugs known as statins. ... established cardiovascular disease but with cardiovascular risk factors, statin use ...
... LOS ANGELES, July 8 Social Compassion in ... reducing pet overpopulation through legislation, today reported that the ... California municipal shelters increased 14.6 percent statewide - from ... recently released figures from the California Department of Public ...
... drug use, delivery made a measurable impact in Planned ... Two changes to the way Planned Parenthood clinics perform ... the rate of serious infections, a new report says. ... the area between the gum and the cheek (buccal ...
... DIEGO, July 8 Volcano Corporation (Nasdaq: VOLC ... products for the diagnosis of coronary and peripheral artery disease, ... largest distributor in Japan, Goodman Company, Ltd. This agreement, ... transition to a direct sales force in the market to ...
Cached Medicine News:Health News:Stimulus Funds Support VA Energy Conservation Efforts 2Health News:The next health tsunami: Noncommunicable diseases 2Health News:British Medical Journal Report Supports SCHS White Paper on Statins 2Health News:California Department of Public Health Reports Large Increase in Pet Euthanasia 2Health News:California Department of Public Health Reports Large Increase in Pet Euthanasia 3Health News:Changes Reduced Infections From Medical Abortion 2Health News:Changes Reduced Infections From Medical Abortion 3Health News:Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman 2Health News:Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman 3Health News:Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman 4Health News:Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman 5
... monitor elevates bedside glucose testing to a ... the quality of central laboratory testing. ... strip technology. Current glucose strips use ... system measures and corrects hematocrit interference as ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... BreatheX is a wearable CPAP (Continuous Positive ... sleep apnea. The lightweight BreatheX CPAP device ... with its built-in, rechargeable battery, and is ... no longer need to be "plugged in ...
Paraffin Block Storage System...
Medicine Products: